![]() |
市場調查報告書
商品編碼
2169676
骨關節炎治療市場預測至2034年-按藥物類別、給藥途徑、受影響部位、病患類型、分銷管道、最終用戶和地區分類的全球分析Osteoarthritis Therapeutics Market Forecasts to 2034 - Global Analysis By Drug Class, Route of Administration, Disease Site, Patient Type, Distribution Channel, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,到 2026 年,全球骨關節炎治療市場規模將達到 98 億美元,預計在預測期內將以 6.7% 的複合年成長率成長,到 2034 年將達到 165 億美元。
骨關節炎治療市場主要集中在旨在緩解疼痛、減輕發炎、改善關節功能以及控制退化性關節疾病相關症狀的藥物療法。骨關節炎盛行率的不斷上升、老年人口的成長以及肥胖和關節相關疾病發病率的增加正在推動市場成長。注射療法、緩釋製劑以及新興的緩解疾病骨關節炎療法的進步正在創造商機。整形外科醫療基礎設施的擴建以及對長期關節健康管理的日益重視,進一步促進了全球治療創新和市場發展。
骨關節炎盛行率不斷上升以及老年人口不斷增加。
骨關節炎盛行率的上升推動了對有效治療方法的需求。人口老化、肥胖率上升、關節損傷發生率增加,都加重了退化性關節疾病的負擔。骨關節炎通常影響負重關節,導致慢性疼痛、僵硬和活動受限。人們對早期診斷和症狀管理的認知不斷提高,正在加速治療方法的普及。整形外科醫療服務的覆蓋範圍擴大以及對長期疼痛管理需求的增加,進一步推動了市場成長。
緩解疾病治療選擇有限,現有治療有副作用
經證實有效的緩解疾病治療方案數量有限,阻礙了市場成長。目前市面上許多骨關節炎藥物的主要目標是控制疼痛和炎症,而非逆轉軟骨退化或阻止疾病進展。長期使用非類固醇消炎劑(NSAIDs)會增加消化器官系統、心血管和腎臟風險,尤其是老年患者。此外,治療效果的差異、對重複注射的擔憂以及醫療覆蓋範圍的不完善也會影響這些療法的普及。新興療法的高成本可能會進一步限制其在醫療保健系統中的可近性。
緩釋注射藥物和骨關節炎病理改良療法的進展
緩釋藥物遞送系統、再生醫學以及骨關節炎病理機制改善療法的研究進展正在創造巨大的市場機會。製藥公司正在研發針對發炎、軟骨劣化和關節組織保護的療法。緩釋注射劑有望透過減少給藥頻率來提高治療的便利性。人們對精準醫療、生物學方法和局部給藥的興趣日益濃厚,正在推動創新。對臨床試驗投入的增加以及製藥公司與研究機構之間合作的加強,進一步促進了療法的研發。
新型骨關節炎治療藥物的學名藥面臨激烈的競爭和嚴格的監管要求。
學名藥競爭加劇和監管要求日益嚴格,對市場構成重大威脅。廣泛上市的非專利鎮痛藥和非類固醇消炎劑正對品牌藥的價格構成壓力。開發創新骨關節炎療法的公司必須通過大規模臨床試驗,證明其產品在疼痛、功能和安全性方面具有臨床意義的改善。疾病異質性、安慰劑效應以及長期治療評估等挑戰,都可能使法規核准變得複雜。此外,保險報銷限制、安全隱患以及來自非藥物療法的競爭也會影響市場發展。
新冠疫情對骨關節炎治療市場造成了衝擊,整形外科預約中斷、擇期手術延遲以及常規關節護理服務減少。就醫限制導致部分注射療法和復健服務的安排被打亂。患者身體活動的減少和就醫習慣的改變也影響了慢性關節疾病患者的症狀管理。疫情過後,醫療機構恢復了門診整形外科諮詢,並擴大了遠端醫療諮詢的範圍。對慢性病管理、疼痛緩解和維持活動能力的重新重視,支撐了治療需求的持續成長。
在預測期內,非類固醇消炎劑(NSAID) 細分市場預計將佔據最大的市場佔有率。
鑑於非類固醇消炎劑(NSAID) 在治療骨關節炎相關疼痛和發炎方面的廣泛應用,預計在預測期內,NSAID 細分市場將佔據最大的市場佔有率。口服和外用 NSAID 通常是症狀性關節疾病患者治療方案中的常用藥物。其廣泛的可及性、較高的臨床認可度以及相對經濟實惠的學名藥的出現,推動了其應用。膝關節、髖關節和手部骨關節炎盛行率的不斷上升也促進了需求的成長。外用製劑和個人化治療方案的進步進一步推動了該細分市場的發展,並促進了更安全的用藥。
預計在預測期內,透明質酸產品細分市場將呈現最高的複合年成長率。
在預測期內,透明質酸產品細分市場預計將呈現最高的成長率,這主要得益於人們對注射式黏彈性替代療法的持續關注,該療法適用於膝骨關節炎的特定患者。這些產品旨在透過關節內給藥改善關節潤滑並緩解症狀。交聯透明質酸製劑、緩釋注射劑和聯合療法的進步正在推動產品開發。然而,由於治療效果不穩定,臨床指引對於常規黏彈性替代療法的適用性存在分歧。儘管如此,對非手術關節管理方案日益成長的需求可能會帶來商業性機會。
在預測期內,北美預計將佔據最大的市場佔有率,這得益於其先進的整形外科醫療基礎設施、可觀的藥品支出以及人口老齡化導致的骨關節炎患病率上升。美國和加拿大已建立起完善的醫療保健體系,提供藥物鎮痛、注射療法和專業的整形外科護理。大型製藥公司和臨床研究機構的存在也為治療創新提供了支持。對慢性關節疼痛管理的需求不斷成長,以及人們對維持活動能力的意識日益增強,進一步推動了該地區的市場發展。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於老年人口的成長、骨關節炎患病率的上升以及整形外科醫療服務可及性的提高。中國、印度、日本、韓國和澳洲在肌肉骨骼疾病的管理能力和藥品分銷網路方面均有所增強。肥胖率的上升、關節健康意識的增強以及醫療保健支出的成長,都推動了對治療的需求。此外,學名藥、注射劑和新型骨關節炎療法的日益普及,也進一步促進了該地區的市場成長。
According to Stratistics MRC, the Global Osteoarthritis Therapeutics Market is accounted for $9.8 billion in 2026 and is expected to reach $16.5 billion by 2034 growing at a CAGR of 6.7% during the forecast period. The Osteoarthritis Therapeutics Market focuses on pharmaceutical treatments designed to relieve pain, reduce inflammation, improve joint function, and manage symptoms associated with degenerative joint diseases. Increasing prevalence of osteoarthritis, growing elderly populations, and rising incidence of obesity and joint-related disorders are supporting market growth. Advancements in injectable therapies, sustained-release drug formulations, and emerging disease-modifying osteoarthritis treatments are creating commercial opportunities. Expanding orthopedic healthcare infrastructure and increasing emphasis on long-term joint health management are further encouraging therapeutic innovation and market development worldwide.
Increasing prevalence of osteoarthritis and growing geriatric population
The rising prevalence of osteoarthritis is driving demand for effective therapeutic solutions. Increasing elderly populations, growing obesity rates, and higher incidence of joint injuries are contributing to the burden of degenerative joint disorders. Osteoarthritis commonly affects weight-bearing joints, resulting in chronic pain, stiffness, and reduced mobility. Growing awareness of early diagnosis and symptom management is encouraging treatment adoption. Expanding access to orthopedic healthcare services and increasing demand for long-term pain management are further supporting market growth.
Limited disease-modifying treatment options and adverse effects of existing therapies
Limited availability of proven disease-modifying treatments is restraining market growth. Most currently available osteoarthritis medications primarily manage pain and inflammation rather than reversing cartilage degeneration or preventing disease progression. Long-term use of nonsteroidal anti-inflammatory drugs may increase gastrointestinal, cardiovascular, and renal risks, particularly among older patients. Additionally, variable treatment responses, concerns regarding repeated injections, and inconsistent reimbursement coverage can affect therapeutic adoption. High costs associated with emerging treatments may further restrict accessibility across healthcare systems.
Advancements in sustained-release injectables and disease-modifying osteoarthritis therapies
Advancements in sustained-release drug delivery systems, regenerative medicine, and disease-modifying osteoarthritis research are creating significant market opportunities. Pharmaceutical companies are investigating therapies targeting inflammation, cartilage degradation, and joint tissue preservation. Extended-release injectable formulations may improve treatment convenience by reducing administration frequency. Growing interest in precision medicine, biologic approaches, and localized drug delivery is encouraging innovation. Increasing investment in clinical trials and partnerships between pharmaceutical manufacturers and research institutions is further supporting therapeutic development.
Generic competition and stringent regulatory requirements for emerging osteoarthritis therapies
Growing generic competition and stringent regulatory requirements present significant market threats. Widely available generic analgesics and nonsteroidal anti-inflammatory drugs create pricing pressure for branded pharmaceutical products. Developers of innovative osteoarthritis therapies must demonstrate clinically meaningful improvements in pain, function, and safety through extensive clinical trials. Challenges associated with disease heterogeneity, placebo responses, and long-term treatment assessment may complicate regulatory approval. Additionally, reimbursement restrictions, safety concerns, and competition from nonpharmacological treatment approaches can influence market development.
The COVID-19 pandemic affected the osteoarthritis therapeutics market through disruptions in orthopedic consultations, delayed elective procedures, and reduced access to routine joint care. Restrictions on healthcare visits interrupted certain injectable treatment schedules and rehabilitation services. Reduced physical activity and changes in healthcare-seeking behavior also influenced symptom management among patients with chronic joint disorders. Following the pandemic, healthcare providers resumed outpatient orthopedic services and expanded telemedicine consultations. Renewed emphasis on chronic disease management, pain relief, and mobility preservation supported continued therapeutic demand.
The nonsteroidal anti-inflammatory drugs (NSAIDs) segment is expected to be the largest during the forecast period
The nonsteroidal anti-inflammatory drugs (NSAIDs) segment is expected to account for the largest market share during the forecast period due to its widespread use in managing osteoarthritis-related pain and inflammation. Oral and topical NSAIDs are commonly incorporated into treatment strategies for patients experiencing symptomatic joint disorders. Their broad availability, established clinical familiarity, and relatively affordable generic options support adoption. Increasing prevalence of knee, hip, and hand osteoarthritis is contributing to demand. Advancements in topical formulations and individualized treatment approaches are further supporting segment development while encouraging safer medication utilization.
The hyaluronic acid products segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the hyaluronic acid products segment is predicted to witness the highest growth rate due to continued interest in injectable viscosupplementation for selected patients with knee osteoarthritis. These products aim to improve joint lubrication and alleviate symptoms through intra-articular administration. Advancements in cross-linked hyaluronic acid formulations, extended-duration injections, and combination delivery approaches are supporting product development. However, clinical guidelines differ regarding routine viscosupplementation because treatment benefits are inconsistent. Growing demand for nonsurgical joint management options may nevertheless support commercial opportunities.
During the forecast period, North America is expected to hold the largest market share, supported by advanced orthopedic healthcare infrastructure, substantial pharmaceutical expenditure, and increasing prevalence of osteoarthritis among aging populations. The United States and Canada have established healthcare systems offering pharmaceutical pain management, injectable treatments, and specialist orthopedic care. The presence of major pharmaceutical manufacturers and clinical research organizations supports therapeutic innovation. Growing demand for chronic joint pain management and increasing awareness of mobility preservation are further strengthening regional market development.
Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR due to expanding elderly populations, increasing osteoarthritis prevalence, and improving access to orthopedic healthcare services. China, India, Japan, South Korea, and Australia are strengthening musculoskeletal disease management capabilities and pharmaceutical distribution networks. Rising obesity rates, growing awareness of joint health, and increasing healthcare expenditure are supporting therapeutic demand. Expanding availability of generic medications, injectable treatments, and emerging osteoarthritis therapies is further encouraging regional market growth.
Key players in the market
Some of the key players in the Osteoarthritis Therapeutics Market include Biosplice Therapeutics, Inc., Eupraxia Pharmaceuticals Inc., Novartis AG, 4P-Pharma, Genascence Corporation, Bioventus Inc., Zimmer Biomet Holdings, Inc., Anika Therapeutics, Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Johnson & Johnson, GSK plc, Ferring Pharmaceuticals, Bayer AG, Fidia Farmaceutici S.p.A., Pacira BioSciences, Inc., and Amgen Inc.
In February 2026, Anika Therapeutics reported its full-year 2025 financial results, highlighting continued commercial performance in its osteoarthritis pain management and regenerative solutions businesses. The company reported $112.8 million in annual revenue and 15% growth in its commercial channel.
In July 2025, Genascence Corporation announced that the U.S. Food and Drug Administration had granted Regenerative Medicine Advanced Therapy designation to GNSC-001, its investigational gene therapy for knee osteoarthritis. The designation followed clinical development evaluating the therapy's safety and biological activity.
In April 2025, Eupraxia Pharmaceuticals announced the presentation of additional clinical findings from its Phase 2 SPRINGBOARD study evaluating EP-104IAR for knee osteoarthritis. The extended-release intra-articular formulation of fluticasone propionate demonstrated sustained pain responses in a defined patient subgroup.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.